- One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancer
- Two preclinical posters characterizing new developments from the enLIGHTEN™ Discovery Platform
NEEDHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the Company will present three posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting taking place November 3-5, 2023 in San Diego, CA and virtually.
Presentation details are as follows:
- CAN-2409 – Pancreatic Cancer
- Poster Presentation Title: Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC)
- Presenter: Garrett Nichols, MD, MS, Chief Medical Officer, Candel Therapeutics
- Abstract Number: 653
- Session Date/Time: Friday, November 3, 2023, 9 am – 7 pm PT
- Location: Exhibit Halls A and B1 – San Diego Convention Center
- Poster Presentation Title: Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC)
- enLIGHTEN™ Discovery Platform
- Poster Presentation Title: A novel viral immunotherapeutic targeting the CD47/SIRP? axis demonstrates potent anti-tumor effects
- Presenter: Anne R. Diers, PhD, Senior Director, Research, Candel Therapeutics
- Abstract Number: 1096
- Session Date/Time: Saturday, November 4, 2023, 9 am – 8:30 pm PT
- Location: Exhibit Halls A and B1 – San Diego Convention Center
- Poster Presentation Title: Development of enLIGHTEN™ Alpha-201 herpes simplex viral vectors encoding payloads targeting the tumor microenvironment
- Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics
- Abstract Number: 1348
- Session Date/Time: Saturday, November 4, 2023, 9 am – 8:30 pm PT
- Location: Exhibit Halls A and B1 – San Diego Convention Center
- Poster Presentation Title: A novel viral immunotherapeutic targeting the CD47/SIRP? axis demonstrates potent anti-tumor effects
Further details from the presentations will be available following the events on the Candel website at: www.candeltx.com/media
About CAN-2409
CAN-2409, Candel's most advanced viral immunotherapy candidate, is an investigational off-the-shelf replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient's specific tumor and induce an individualized, systemic immune response against the disease. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells. The intra-tumoral administration results in the release of tumor-specific neoantigens in the microenvironment. At the same time, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the ...